Navigation Links
Cephalon Exercises its Option to Acquire BioAssets Development Corporation
Date:10/21/2010

FRAZER, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire BioAssets Development Corporation (BDC), following receipt of interim data from a Phase II placebo-controlled proof-of-concept study evaluating epidural administration of a tumor necrosis factor (TNF) inhibitor for the treatment of sciatica in 45 patients. Sciatica is a neuropathic inflammatory pain condition that occurs when the sciatic nerve is compressed, injured or irritated.  As part of the acquisition, Cephalon will gain rights to the BDC intellectual property estate covering the use of cytokine inhibitors, including TNF inhibitors, for sciatic pain in patients with intervertebral disk herniation, as well as other spinal disorders.  The transaction is expected to close in mid-November.  

Separately, Cephalon will evaluate epidural administration of its proprietary domain antibody TNF inhibitor, CEP 37247, in a Phase II program. "With this acquisition, Cephalon combines BDC's intellectual property and scientific expertise regarding TNF inhibitors with our own pipeline," said Dr. Lesley Russell, Chief Medical Officer for Cephalon. "The BDC data provide a path forward to evaluate a potential non-surgical approach for the treatment of patients suffering from the debilitating effects of sciatica."

Dr. James Gorman, CEO and Chief Medical Officer for BDC commented, "The Cephalon commitment to develop CEP 37247 for non-operative treatment of sciatic pain is encouraging news for the patients, physicians and payors urgently seeking a more effective non-operative treatment for this prevalent, debilitating condition.  We believe that the combination of BDC's assets with the Cephalon expertise and pipeline greatly increases the potential to provide in the foreseeable future an FDA-approved TNF-inhibitor therapeutic for s
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... 2010 AstraZeneca (NYSE: ... it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and ... mixed dyslipidemia. This means the co-development and license agreement with ... A Complete Response Letter (CRL) for the CERTRIAD New Drug ...
... Inc (NYSE: PFE ) today announced that ... States Food and Drug Administration (FDA) and the European ... 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to ... prevention of pneumococcal disease caused by the 13 serotypes ...
Cached Medicine Technology:Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 2Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 3Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 4Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older 5
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is ... the business has announced its bamboo flooring promotion ... best material from certified suppliers, and offers the ... worldwide. In the current promotion, all customers can ... when they say they know BambooIndustry.com from press ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 ... the healthcare sector have benefited the Massage Services ... the discretionary characteristics of industry products, the anticipated 1.0% ... five-year period has provided consumers with the means to ... that have received a massage in a given year ...
(Date:12/20/2014)... 20, 2014 The print component of ... a distribution of approximately 160,000 copies and an estimated ... through a vast social media strategy and across a ... explore the digital version of the campaign, click ... interview with the ladies of CTV’s The Social. ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New ... a decade. They’ve treated over 40,000 patients while carrying ... alternative to the Paramus area. , For 2015, ... their staff of top-notch board certified physicians: Christine Milosis MD, ... These new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: ... birthday focused portal on December 17th, 2014. , ... both US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 ... , Features, Choose from thousands of stock photos to ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... criticized Advanced Cells Therapeutics, which provided stem cell therapy for ... better than conventional treatments and her illness has not improved. ... Bryson said, "I'm back to where I was before the ... hope it was going to work and it didn't. I ...
... Australians live longer but with more disabilities among the aged. While ... in 1988, more people are suffering disabilities later in life, according ... ,Life expectancy for non-Indigenous Australian men has increased by ... 2003 can expect to live up to 77 and women up ...
... of Punjab and Haryana - will soon have 20 condom ... ,The machines will be installed by the state AIDS ... operate, insure and refill these machines, an official spokesman said. ... men's toilets at various places. ,The points identified ...
... may result from the body overshooting as it tries ... suggests new research// from the University of Massachusetts Amherst ... to a different time zone, the researchers recommend advancing ... allowing the body’s clocks to remain coordinated. The work ...
... results of a Canadian study, a multivitamin pill should ... to reduce risks of having a child with birth ... possibility of a wide range of severe birth defects ... hydrocephalus, heart malformations, truncated or missing limbs, urinary-tract abnormalities ...
... have a deleterious effect on young, developing brains, according ... toddlers is linked to lower IQ scores later in ... problems like diabetes, high cholesterol and hypertension is a ... professor of pediatric genetics at the University of Florida ...
Cached Medicine News:Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 2Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 3Health News:Prenatal multivitamins reduce birth defects 2Health News:Prenatal multivitamins reduce birth defects 3Health News:IQ of Toddlers Affected by Excess weight 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: